e-ISSN: Pending
Negative / Null Result ReportBiochemistry, Genetics and Molecular Biology· cited by 63

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O’Shaughnessy; Hartmut Koeppen; Yuanyuan Xiao; Mark R. Lackner; Devchand Paul; Christopher Stokoe; John Pippen; Lea Krekow · 2015 · Clinical Cancer Research

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

PURPOSE: We conducted a randomized phase III study to determine whether patients with early breast cancer would benefit from the addition of capecitabine (X) to a standard regimen of doxorubicin (A) plus cyclophosphamide (C) followed by…

Excerpt shown for reference under fair use — read the full paper at the publisher.

Read full paper at publisher

Hosted by the publisher — may require access.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1158/1078-0432.ccr-15-0636